Two non-governmental organizations said that the European Union is putting the interests of big drug companies ahead of those of millions of people without access to essential medicines.
The EU's executive arm, the European Commission, was also accused of acting against the spirit of world trade rules, in a new report by Oxfam International and Health Action International (HAI).
Imphal Pharmacists' Protest Against Monetary Demands by Militants
75 pharmacies functioning in Porompat, Imphal have become the latest victims of monetary demands by militants.
Advertisement
The report said the EU was leading a heavy-handed investigation into intellectual property abuses in the pharmaceutical sector which has driven up prices and deprived developing countries of generic medicines.
"A crackdown on European pharmaceutical prices is happening alongside a concerted effort to further push intellectual property rules that prevent poor countries from buying affordable medicines," said Oxfam official Elise Ford.
![Researchers Suggest Patent Challenges Reduce Pharmaceutical Innovation and Productivity]( "Researchers Suggest Patent Challenges Reduce Pharmaceutical Innovation and Productivity")
An article published in this week's issue of the journal Science says that the development of new and innovative pharmaceuticals is being stifled by a U.S. law
"Millions of poor people have to pay for medicines out of their own pockets so even a small price rise can make them unaffordable. Europe's policies are directly responsible for this scandal," she said.
The policy, the report said, has increased the price of medicines and this hits poorer people hardest. It said other policies were delaying the passage of generic medicines and obstructing research.
The measures end up supporting the commercial interests of the pharmaceutical industry, while limiting access to drugs and reducing opportunities make more innovative products, the NGOs said.
"The EU must accept its moral and legal obligations. There is growing evidence that the EU's trade agenda is causing severe damage to public health in developing countries," said HAI's Sophie Bloemen.
Source: AFP
ARU
Researchers Suggest Patent Challenges Reduce Pharmaceutical Innovation and Productivity
An article published in this week's issue of the journal Science says that the development of new and innovative pharmaceuticals is being stifled by a U.S. law
Advertisement
"Millions of poor people have to pay for medicines out of their own pockets so even a small price rise can make them unaffordable. Europe's policies are directly responsible for this scandal," she said.
The policy, the report said, has increased the price of medicines and this hits poorer people hardest. It said other policies were delaying the passage of generic medicines and obstructing research.
The measures end up supporting the commercial interests of the pharmaceutical industry, while limiting access to drugs and reducing opportunities make more innovative products, the NGOs said.
"The EU must accept its moral and legal obligations. There is growing evidence that the EU's trade agenda is causing severe damage to public health in developing countries," said HAI's Sophie Bloemen.
Source: AFP
ARU
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest General Health News
The Pakistan Ministry has announced the commencement of a nationwide polio vaccination campaign beginning on October 2, aiming to immunize more children.
In a tragic incident, a woman in the US experienced the loss of all her limbs as a result of a bacterial outbreak linked to the consumption of contaminated fish.
FluMos-v2, a unique universal influenza vaccine candidate, undergoing a phase 1 trial at NIH, increases recipients' immunity against many influenza viruses.
In Pakistan, the polio campaign focuses on more than 270,000 children under the age of five years, residing in areas with insufficient vaccine coverage.
Dangers of Wrong Diagnosis: Diagnostic errors in healthcare can increase the risk of permanent disabilities and deaths.
